Dupilumab for the Treatment of Moderate and Severe Atopic Dermatitis: Real-life Experience

Overview

Journal Postepy Dermatol Alergol

Publisher Termedia

Specialty Allergy & Immunology

Date 2024 Jan 29

PMID 38282886

Authors

Jowita Sroka-Tomaszewska

Barabara Bulinska

Aleksandra Wilkowska

Roman J Nowicki

Magdalena Trzeciak

Affiliations

Soon will be listed here.

Abstract

Introduction: Atopic dermatitis is a relapsing, chronic, inflammatory dermatosis. So far, treatment options for more severe forms of the disease have been limited. The prospect has changed with the advent of biological drug registrations. Dupilumab is a monoclonal antibody targeting the a subunit of the IL-4 receptor and is responsible for blocking the signalling of interleukin (IL) 4 (IL-4) and IL-13. Clinical trials conducted for over 10 years have confirmed the efficacy and safety of dupilumab's treatment for atopic dermatitis.

Aim: Evaluating the efficacy of dupilumab treatment in patients with moderate and severe atopic dermatitis in real life.

Material And Methods: We retrospectively evaluated medical records of patients treated with dupilumab for atopic dermatitis at the Department of Dermatology, Venereology and Allergology in Gdansk.

Results: Ten patients in total were studied. They received dupilumab with standard dosing. The mean percentage reduction in SCORAD score was 52.16% in 8 weeks. Dupilumab was generally well tolerated and did not cause serious side effects. The most common adverse event was conjunctivitis.

Conclusions: Dupilumab is an effective disease-modifying drug for patients with moderate to severe atopic dermatitis. The effects of treatment in real life are consistent with those demonstrated in clinical trials.

References

Nettis E, Ferrucci S, Ortoncelli M, Pellacani G, Foti C, Di Leo E . Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study. J Investig Allergol Clin Immunol. 2020; 32(2):124-132. DOI: 10.18176/jiaci.0641. View

Aszodi N, Thurau S, Seegraber M, de Bruin-Weller M, Wollenberg A . Management of dupilumab-associated conjunctivitis in atopic dermatitis. J Dtsch Dermatol Ges. 2019; 17(5):488-491. DOI: 10.1111/ddg.13809. View

Tavecchio S, Angileri L, Pozzo Giuffrida F, Germiniasi F, Marzano A, Ferrucci S . Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients. J Clin Med. 2020; 9(9). PMC: 7564127. DOI: 10.3390/jcm9092684. View

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A . Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018; 32(5):657-682. DOI: 10.1111/jdv.14891. View

Cork M, Thaci D, Eichenfield L, Arkwright P, Sun X, Chen Z . Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2020; 184(5):857-870. PMC: 8247037. DOI: 10.1111/bjd.19460. View

Sastre J, Davila I . Dupilumab: A New Paradigm for the Treatment of Allergic Diseases. J Investig Allergol Clin Immunol. 2018; 28(3):139-150. DOI: 10.18176/jiaci.0254. View

Boothe W, Tarbox J, Tarbox M . Atopic Dermatitis: Pathophysiology. Adv Exp Med Biol. 2017; 1027:21-37. DOI: 10.1007/978-3-319-64804-0_3. View

Thaci D, Simpson E, Deleuran M, Kataoka Y, Chen Z, Gadkari A . Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019; 94(2):266-275. DOI: 10.1016/j.jdermsci.2019.02.002. View

Bosma A, de Wijs L, Hof M, van Nieuwenhuizen B, Gerbens L, Middelkamp-Hup M . Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Am Acad Dermatol. 2020; 83(5):1375-1384. DOI: 10.1016/j.jaad.2020.05.128. View

10.

Ou Z, Chen C, Chen A, Yang Y, Zhou W . Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis. Int Immunopharmacol. 2017; 54:303-310. DOI: 10.1016/j.intimp.2017.11.031. View

11.

Puar N, Chovatiya R, Paller A . New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2020; 126(1):21-31. DOI: 10.1016/j.anai.2020.08.016. View

12.

Simpson E, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L . Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2016; 75(3):506-515. DOI: 10.1016/j.jaad.2016.04.054. View

13.

Avena-Woods C . Overview of atopic dermatitis. Am J Manag Care. 2017; 23(8 Suppl):S115-S123. View

14.

Cork M, Eckert L, Simpson E, Armstrong A, Barbarot S, Puig L . Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2019; 31(6):606-614. DOI: 10.1080/09546634.2019.1612836. View

15.

Paller A, Siegfried E, Simpson E, Cork M, Lockshin B, Kosloski M . A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2020; 35(2):464-475. PMC: 7894166. DOI: 10.1111/jdv.16928. View

16.

Thomson J, Wernham A, Williams H . Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal. Br J Dermatol. 2018; 178(4):897-902. DOI: 10.1111/bjd.16317. View

17.

Harb H, Chatila T . Mechanisms of Dupilumab. Clin Exp Allergy. 2019; 50(1):5-14. PMC: 6930967. DOI: 10.1111/cea.13491. View

18.

Paller A, Bansal A, Simpson E, Boguniewicz M, Blauvelt A, Siegfried E . Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2019; 21(1):119-131. PMC: 6989562. DOI: 10.1007/s40257-019-00478-y. View

19.

Thaci D, Simpson E, Beck L, Bieber T, Blauvelt A, Papp K . Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2015; 387(10013):40-52. DOI: 10.1016/S0140-6736(15)00388-8. View

20.

Gooderham M, Hong H, Eshtiaghi P, Papp K . Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018; 78(3 Suppl 1):S28-S36. DOI: 10.1016/j.jaad.2017.12.022. View